Forbes: “Meet the Collaboration Solving Some of Antibody Discovery’s Toughest Problems”

Today’s biotechnology scientists and companies are focused more on working together in the drug and therapy development process to benefit society rather than competition. Genovac Antibody Discovery is pleased to be at the forefront of this type of collaborative problem-solving through our partnership with digital cell biology company Berkeley Lights. By combining its Beacon® Optofluidic System for single-cell screening and our advanced genetic immunization technology, we’re now discovering more antibodies faster, which gives our clients a head start in achieving your goals. 

Read about Genovac, Berkeley Lights and the “new era of biotechnology” in this May 25, 2021 Forbes piece by John Cumbers.